Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin.

James W Wheless1, R Eugene Ramsay, Stephen D Collins

  • 1University of Tennessee Health Science Center, Le Bonheur Children's Medical Center, Memphis, Tennessee, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased interval between seizure clusters across time in pediatric patients treated with the immediate-use seizure medication diazepam nasal spray.

Epilepsia·2026
Same author

Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy: Three-Year Efficacy and Interim Safety Results.

Neurology·2026
Same author

Utilization of Stiripentol in Children With Developmental and Epileptic Encephalopathies: Considerations for Clinical Practice.

Pediatric neurology·2026
Same author

State-of-the-Art Management of Children with Intractable Epilepsy and Brain Tumors.

Pediatric neurosurgery·2026
Same author

Safety and effectiveness of diazepam nasal spray in patients with Rett syndrome and seizure clusters: <i>post hoc</i> analyses from a long-term safety study and survey of severity and burden.

Frontiers in neurology·2026
Same author

Zorevunersen in Children and Adolescents with Dravet Syndrome.

The New England journal of medicine·2026
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Vigabatrin effectively treats infantile spasms and complex partial seizures, but can cause visual field defects. Early detection and management are key to balancing treatment benefits with potential risks.

Area of Science:

  • Neurology
  • Pharmacology
  • Ophthalmology

Background:

  • Refractory epilepsies like infantile spasms (IS) and complex partial seizures (CPS) significantly impair neurological integrity, quality of life, and increase mortality risk.
  • Early identification of effective pharmacotherapy is crucial for managing these severe seizure types.
  • Vigabatrin is an antiepileptic drug (AED) demonstrating efficacy in various seizure types, including IS and CPS, in both children and adults.

Purpose of the Study:

  • To discuss clinical decision-making regarding vigabatrin use for IS and CPS.
  • To assess the benefits of vigabatrin therapy against the risks of visual field defects (VFD).
  • To inform physicians and patients about the potential risks and management of vigabatrin-associated VFD.

Main Methods:

Related Experiment Videos

  • Review of studies characterizing vigabatrin-associated peripheral visual field defects (VFD).
  • Analysis of VFD onset, prevalence, and severity in patients with IS and CPS.
  • Discussion of available testing methods for early VFD detection and management.

    • Main Results:

    • Vigabatrin-associated peripheral VFD (bilateral, concentric constriction) occurs in 30-50% of patients with long-term exposure, often asymptomatically.
    • VFD onset varies, with earliest observed at 5 months (infants) and 11 months (CPS), averaging 1 year and over 5 years, respectively.
    • Patients with VFD retain an average of 65 degrees of lateral vision (normal: 90 degrees); the idiosyncratic nature of VFD suggests it's not strictly dose- or duration-dependent.

    Conclusions:

    • Vigabatrin is an effective AED for IS and CPS, but carries a risk of peripheral VFD.
    • Most patients with VFD remain asymptomatic, and its idiosyncratic nature warrants careful consideration.
    • Effective testing methods exist for early VFD detection, enabling informed clinical decisions on vigabatrin therapy.